What are the treatment options for a client with a recent diagnosis of melanoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment Options for Melanoma

The primary treatment for melanoma is surgical excision with appropriate margins based on the depth of invasion, with additional treatments determined by staging and risk factors. 1

Surgical Management

  • Wide local excision is the standard primary treatment for melanoma with safety margins determined by tumor thickness: 0.5 cm for in situ melanomas, 1 cm for tumors up to 2 mm thick, and 2 cm for thicker tumors 1
  • Sentinel lymph node biopsy (SLNB) is recommended for melanomas with a tumor thickness >1 mm and/or ulceration for accurate staging 1, 2
  • Complete lymph node dissection (CLND) is NOT recommended for sentinel node-positive patients but IS indicated for clinically detectable (macroscopic) lymph node metastases 1
  • Mohs surgery is NOT a standard procedure for melanoma treatment - this technique is primarily used for non-melanoma skin cancers 2, 3

Treatment by Stage

Early Stage Melanoma (Stage 0-IIA)

  • Stage 0 (in situ) and early-stage melanoma (Stage IA, ≤1 mm without adverse features): Primary excision alone is typically curative 1
  • Stage IB or II (≤1.0 mm with ulceration or Clark level IV-V, or ≥1.0 mm thick): Wide excision with appropriate margins 1
  • No adjuvant therapy is standard for stage IA; observation is recommended 1

Intermediate Stage Melanoma (Stage IIB-IIC)

  • Wide excision with 2 cm margins 1
  • Adjuvant options include anti-PD-1 immunotherapy (pembrolizumab or nivolumab) which has shown improved recurrence-free survival 1, 2

Advanced Melanoma (Stage III-IV)

  • Stage III: Surgical management plus adjuvant therapy 1
  • Adjuvant options include anti-PD-1 therapy (nivolumab, pembrolizumab) or BRAF/MEK inhibitor combination (dabrafenib/trametinib) for BRAF-mutated melanoma 1, 2
  • Stage IV (metastatic): Treatment depends on whether disease is limited (resectable) or disseminated (unresectable) 1
  • For limited metastatic disease: Surgical resection when feasible 1
  • For disseminated disease: Systemic therapy options include anti-PD-1 antibodies (pembrolizumab, nivolumab), combination of PD-1 and ipilimumab, or BRAF/MEK inhibitors for BRAF-mutated melanoma 1

Important Clarifications

  • Dermabrasion or chemical peels are NOT appropriate treatments for melanoma - these are cosmetic procedures used for conditions like acne scarring or melasma, not for treating skin cancer 4, 5
  • Lymph node resection during Mohs surgery is NOT standard practice - Mohs surgery is not typically used for melanoma, and lymph node assessment is done through sentinel lymph node biopsy as a separate procedure 3, 6
  • Melanoma treatment is NOT limited to "small excision with local anesthetic" - the extent of surgery depends on tumor thickness and staging 1, 2
  • Eight weeks of radiation therapy is NOT a standard primary treatment for melanoma - radiation is primarily used in specific situations such as for palliation of symptoms or local control in cases of inadequate margins 1

Follow-up Care

  • Lifelong regular skin self-examinations and professional skin checks are recommended 1
  • Patients should be educated about sun protection and avoidance of UV exposure 1, 5
  • Family members should be informed of their increased melanoma risk 1
  • Follow-up schedules vary, but typically include visits every 3 months during the first 3 years and every 6-12 months thereafter 1
  • Imaging studies may be appropriate for high-risk patients but are not routinely needed for those with thin primary melanomas 1

Treatment Decision Factors

  • Tumor thickness (Breslow depth) 1, 3
  • Presence of ulceration 1
  • Lymph node involvement 1
  • BRAF mutation status (for advanced disease) 1
  • Patient's overall health and ability to tolerate treatments 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Melanoma: Diagnosis and Treatment.

American family physician, 2024

Guideline

Treatment Approaches for Resistant Melasma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Malignant Melanoma: Skin Cancer-Diagnosis, Prevention, and Treatment.

Critical reviews in eukaryotic gene expression, 2020

Research

Skin Cancer: Melanoma.

FP essentials, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.